Recurrent Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allografts Treated With Anti-CD20 Antibodies
Conclusions.
Rituximab treatment of early PGNMID recurrence is effective, resulting in reasonable, long-term graft survival. Whether pretransplant rituximab modifies the course of recurrence requires additional studies.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
More News: Bone Graft | Glomerulonephritis | Kidney Transplant | Kidney Transplantation | Proteinuria | Rituxan | Study | Transplant Surgery | Transplants | Urology & Nephrology